Niagen Bioscience, Inc.
Niagen Bioscience, Inc. develops and commercializes Niagen-branded nicotinamide riboside products across consumer supplements, ingredient supply, and pharmaceutical applications. The company operates through consumer products, ingredients, and pharmaceutical-oriented research activities, with sales in the United States and select international markets.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaFinished dietary supplement products sold under the Tru Niagen® brand and related practitioner-facing test kits.
Food-grade and pharmaceutical-grade Niagen® ingredients sold to manufacturers, outsourcing facilities, and compounding pharmacies.
Natural product fine chemicals and related research services historically sold to technical and research customers.
Research and development of a therapeutic candidate for rare advanced aging diseases, without commercial sales.
Asiakkaat
The company sells to consumers seeking NAD+ and healthy-aging supplements, primarily through Tru Niagen® and related direct-to-consumer channels. It also sells to commercial partners, manufacturers, FDA-registered 503B outsourcing facilities, and compounding pharmacies that use Niagen ingredients in finished products or compounded formulations. A smaller portion of activity serves technical and research customers that need analytical standards, phytochemicals, or related services.
Consumers purchase Tru Niagen® through the company’s e-commerce channels for daily supplementation and healthy-aging use.
Authorized resellers, marketplaces, and specialty retail partners buy finished products for broader consumer reach.
Consumer-product manufacturers buy food-grade Niagen® as an input for dietary supplement and food formulations.
These customers buy pharmaceutical-grade Niagen® for compounding under applicable regulatory requirements.
Practitioners buy NAD+ test kits and may also support patient access to Niagen Plus-related offerings.
Scientific and laboratory customers buy analytical reference standards and related research services.
Strategia
The company’s strategy centers on expanding Tru Niagen® consumer demand while deepening ingredient adoption with commercial partners and regulated compounding channels. It also uses scientific positioning, regulatory support, and intellectual property protection to differentiate Niagen® as a branded ingredient platform. Longer term, the company is building a pharmaceutical pipeline around its patent portfolio and rare advanced aging disease candidate.
Tru Niagen® is the main commercial engine and supports repeat purchases and brand equity.
Ingredient sales diversify the business and leverage the same core Niagen technology across multiple end markets.
International partners increase addressable market size without building a full direct sales force in every country.
A successful therapeutic program could create a higher-value, patent-protected revenue stream.
Maantiede
The company is headquartered in the United States and generates most of its business there, especially through direct e-commerce, distributors, and ingredient customers. It also sells into select international markets across Asia-Pacific, Europe, the Middle East, and North America, with distribution expanding through regional partners and global e-commerce platforms. Geography matters because product claims, compounding, and ingredient sales are subject to local regulatory requirements and partner availability.
Riskit
The business depends heavily on consumer acceptance of Tru Niagen® and on maintaining effective marketing, distribution, and partner relationships. It also faces regulatory, reputational, and competitive risks because its products operate in wellness, dietary supplement, and compounding channels that are sensitive to claims, compliance, and public perception. Pharmaceutical development adds clinical, regulatory, and intellectual property risk, while the company’s international footprint introduces local-market and partner execution risk.
- Dependence on Tru Niagen® consumer salesVaikutus: KorkeaTodennäköisyys: Kohtalainen
A large share of revenue is tied to one branded product family, so demand softness would affect the whole business.
Kohdistuu: Consumer Products
- Regulatory and compliance riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Dietary supplements, ingredient claims, and compounding activities are subject to FDA, FTC, and local rules.
Kohdistuu: US and international supplement/compounding channels
- Pharmaceutical development uncertaintyVaikutus: KorkeaTodennäköisyys: Matala
Drug development requires successful R&D, regulatory approval, and patent protection before commercialization.
Kohdistuu: Pharmaceutical segment
- Third-party clinic and partner reputation riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The brand can be affected by conduct at clinics or by resellers even when the company does not control operations.
Kohdistuu: Niagen Plus and partner channels
- Competitive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Larger wellness and ingredient companies may outspend the company on marketing, distribution, and product development.
Kohdistuu: Consumer supplements and ingredients
Kirjanpito
Harkinnanvaraiset erätSales occur through multiple channels with different contract terms, discounts, and return patterns.
Vaikutus: Affects net sales timing and comparability across quarters
Management must estimate obligations for future delivery, returns, and customer incentives.
Vaikutus: Can change reported revenue and liabilities
The business relies on licensed and owned intellectual property that is amortized over time.
Vaikutus: Affects operating expense and asset carrying values
Equity awards and option exercises are part of compensation and financing activity.
Vaikutus: Affects operating expense, equity, and cash flow presentation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Qiagen N.V
QGEN · Biological Products, (No Diagnostic Substances)
Neogen Corporation
NEOG · In Vitro & In Vivo Diagnostic Substances
Neogen Corp develops and sells products and services used to test food, feed, and agricultural inputs for safety and quality, while also providing genomics and animal safety solutions.
Nika Pharmaceuticals, Inc
NIKA · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Natural Alternatives International, Inc
NAII · Medicinal Chemicals & Botanical Products
ProtoKinetix, Inc.
PKTX · Pharmaceutical Preparations
Päivitetty: 24.9.2026